Antony D. Loebel, MD | Psychiatrist.com

Original Research

Long-Term Safety and Efficacy of Ziprasidone in Subpopulations of Patients With Bipolar Mania

June 17, 2009

Marcio Versiani, Lewis Warrington, Antony D. Loebel, et al

Original Research

Ziprasidone in Treatment-Resistant Schizophrenia: A 52-Week, Open-Label Continuation Study

September 17, 2007

Antony D. Loebel, Sumant Khanna, Sunita Rajadhyaksha, et al

Original Research

Change in Framingham Risk Score in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, 6-Week Trial of Ziprasidone and Olanzapine

December 15, 2006

Megan C. del Valle, Antony D. Loebel, Stephen Murray Ruoyong, et al

Letter to the Editor

Dr. Addington and Colleagues reply to Methodological Issues in a Comparative Study of Ziprasidone and Risperidone Methodological Issues in a Comparative Study of Ziprasidone and Risperidone

January 16, 2006

Donald E. N. Addington, Christos Pantelis, Antony D. Loebel, et al